Carlos L Arteaga

发表

Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts

Alex J Walsh, Melissa C Skala, Alex J. Walsh, 2015, Journal of biomedical optics.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Norikazu Masuda, Stephen Chia, Mark Clemons, 2017, The Lancet. Oncology.

Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.

Carlos L Arteaga, A. Guerrero-Zotano, C. Arteaga, 2017, Cancer discovery.

Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression.

Carlos L Arteaga, C. Arteaga, N. Dumont, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Carlos L Arteaga, G. Demetri, B. Druker, 2015, Circulation.

Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

Carlos L Arteaga, C. Arteaga, T. Miller, 2011, Breast Cancer Research.

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Gordon B Mills, Carlos L Arteaga, Justin M Balko, 2014, Breast Cancer Research.

A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance

Yu Shyr, Gordon B Mills, Mitch Dowsett, 2011, Clinical Cancer Research.

Type I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase*

Jae Youn Yi, Carlos L Arteaga, C. Arteaga, 2005, Journal of Biological Chemistry.

Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics

Richard M Caprioli, Carlos L Arteaga, Michelle L. Reyzer, 2004, Cancer Research.

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Carlos L Arteaga, Frederick Y. Wu, A. Gazdar, 2006, Cancer cell.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Mithat Gonen, Sarat Chandarlapaty, Neal Rosen, 2008, Cancer research.

Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β

Carlos L Arteaga, C. Arteaga, N. Dumont, 2000, Breast Cancer Research.

A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor

Glenn F Webb, Peter Hinow, Carlos L Arteaga, 2007, Theoretical Biology and Medical Modelling.

A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells.

Carlos L Arteaga, C. Arteaga, N. Dumont, 2003, Biochemical and biophysical research communications.

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells

Yu Shyr, Fei Ye, Carlos L Arteaga, 2010, Breast Cancer Research.

In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.

Alex J Walsh, Melissa C Skala, Alex J. Walsh, 2014, Biomedical optics express.

Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?

Carlos L Arteaga, J. Baselga, C. Arteaga, 2004, Cancer cell.

Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.

Phillip Owens, Rebecca S Cook, Carlos L Arteaga, 2013, Cancer research.

ErbB-targeted therapeutic approaches in human cancer.

Carlos L Arteaga, C. Arteaga, 2003, Experimental cell research.

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Ingrid Meszoely, Sangeeta Bafna, Carlos L Arteaga, 2015, Cancer research.

Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer

Ping Zhao, John C Gore, Donald D. Nolting, 2009, Clinical Cancer Research.

Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

Carlos L Arteaga, C. Arteaga, B. Rexer, 2012, Critical reviews in oncogenesis.

Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.

Alex J Walsh, Melissa C Skala, Alex J. Walsh, 2014, Cancer research.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

William Pao, Vandana G Abramson, Jill Gilbert, 2014, The oncologist.

A Novel Histology-directed Strategy for MALDI-MS Tissue Profiling That Improves Throughput and Cellular Specificity in Human Breast Cancer*

Richard M Caprioli, Carlos L Arteaga, R. Caprioli, 2006, Molecular & Cellular Proteomics.

Brain metastasis: opportunities in basic and translational research.

Carlos L Arteaga, R. DePinho, E. Maher, 2009, Cancer research.

Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.

Richard G Abramson, Carlos L Arteaga, R. Abramson, 2015, Academic radiology.

Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Carlos L Arteaga, J. Engelman, C. Arteaga, 2007, Clinical Cancer Research.

Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.

Alex J Walsh, Melissa C Skala, Alex J. Walsh, 2013, Cancer research.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Yan Guo, Yu Shyr, Nadia Solovieff, 2019, Nature Communications.

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.

Carlotta Costa, Carlos L Arteaga, John M Asara, 2012, Cancer research.

Cdk Inhibitor p27Kip1 and Hormone Dependence in Breast Cancer

Carlos L Arteaga, C. Arteaga, 2004, Clinical Cancer Research.